Revolution Medicines (RVMD) Cash from Operations (2019 - 2026)

Revolution Medicines' Cash from Operations history runs 8 years deep, the most recent figure standing at 354165000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 82.15% year-over-year to 354165000.0 in Q1 2026; TTM through Mar 2026 was 1057471000.0, a 78.83% decrease from a year earlier, with the FY2025 full-year figure at 897741000.0, down 61.05% from the prior year.
• Cash from Operations retreated to 354165000.0 in Q1 2026 per RVMD's latest filing, from 274238000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 51737000.0 in Q3 2022 and bottomed at 354165000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 128167000.0 (2024), against an average of 140253823.53.
• Across the five-year window, Cash from Operations decreased 13.11% in 2023 and slumped 157.34% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 61788000.0 in 2022, then sank by 95.12% to 120563000.0 in 2023, then declined by 14.7% to 138290000.0 in 2024, then slumped by 98.31% to 274238000.0 in 2025, then declined by 29.15% to 354165000.0 in 2026.
• Per Business Quant, the three latest RVMD Cash from Operations figures stand at 354165000.0 (Q1 2026), 274238000.0 (Q4 2025), and 207311000.0 (Q3 2025).